Sunday, October 22, 2017
Home Authors Posts by Cell Tribune

Cell Tribune

38 POSTS 0 COMMENTS
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.

Program Manager, UW Advanced Cellular Therapy

University of Wisconsin's Advanced Cellular Therapy group is hiring a Program Manager. The Program Manager is responsible for all administrative operations, quality assurance, and the...

Servier Appoints MaSTherCell For The Development Of Its CAR-T Cell Therapy...

GERMANTOWN, MD--(Marketwired - January 20, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its...

Caladrius Biosciences Updates Status of Receipt of Funds for a Portion...

BASKING RIDGE, N.J., Jan. 06, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...

Immune cell therapy shows promising results for lymphoma patients

Results from phase I trial using CAR-T therapy with axicabtagene ciloleucel (KTE-C19) show durable complete remission in highly refractory diffuse large B-cell lymphoma patients TAMPA,...

Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration

Agreement Brings Together MD Anderson’s Natural Killer Cell and Affimed’s Antibody-based Technologies Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing...

Stem Cell Therapy Trial at Sanford First of its Kind in...

FDA-approved study explores utility of fat-derived stem cells. The first FDA-approved clinical trial of its kind in the United States using a person’s own fat-derived...

Twenty-two New Patents Are Added To ViaCyte’s Intellectual Property Portfolio

SAN DIEGO, Jan. 4, 2017 ViaCyte, Inc., a privately-held regenerative medicine company, today announced the addition of twenty-two new patents in 2016.  In early 2016...

Using epigenetics to help the immune system fight ovarian cancer –...

Immunotherapy, a cancer treatment approach that’s decades old, has become the hottest subject in oncology. In the past few years, researchers have developed a...

Cells dripped into the brain help man fight a deadly cancer...

Tulsa World reports on the outcome of immunotherapy received by center patient. A great read... City of Hope cancer center patient Richard Grady’s deadly brain cancer...

Intarcia Therapeutics Secures Additional $206M Financing; Gates Foundation to Invest up to...

Intarcia Secures Second Close of the Series EE Equity Financing for an Additional $206M; As Part of the Financing and a New Strategic Initiative,...